Figure 1.

Comparison of vaccine efficacy and effectiveness estimations from clinical trials of RV1 and RV5 against any serotype severe rotavirus gastroenteritis, stratified by country income status.

Note: Efficacies and effectiveness estimates are taken from the following sources (from left to right): Asia,⁸⁶ USA,⁷⁰ Europe,⁷⁰ Europe,⁸⁵ Israel,¹²⁶ Finland,⁸⁴ Australia,⁹² USA,⁷⁵ Latin America,⁷⁰ Brazil,⁸⁹ Finland/Latin America,⁸³ South Africa,⁸⁷ El Salvador,⁹³ Nicaragua,⁷⁶ Sub-Saharan Africa and Southeast Asia,⁷¹ Malawi.⁸⁷

^aThis study took place in a native population characterized by diarrheal pathogens that are similar to lower income settings.^{130 b}Although countries ranged from lower middle to high income, most study countries are from the upper middle income category.